In the Journals

CXL improves corneal steepness, visual acuity

Corneal collagen cross-linking improved maximum K value and corrected and uncorrected distance visual acuity in eyes with corneal ectasia at 1 year, according to a study in Ophthalmology.

A total of 179 patients with corneal ectasia after previous refractive surgery were included.

One group underwent standard corneal collagen cross-linking (CXL) (treatment group), and the control group received riboflavin alone without removal of the epithelium.

In the treatment group, the maximum K value decreased by 0.7 D from baseline to 1 year. It decreased by 2.0 D or more in 14 eyes and increased 2.0 D or more in three eyes.

Corrected distance visual acuity improved by an average of 5.0 logarithm of the minimum angle of resolution (LogMAR) letters, according to researchers.

A total of 23 eyes gained 10 or more LogMAR letters, and three eyes lost 10 or more.

The recent FDA approval of CXL for both the indications of progressive keratoconus and ectasia after refractive surgery represents a major advance in clinical care,” the researchers wrote. – by Abigail Sutton

Disclosure : Hersh is a medical monitor and consultant for Avedro. Please see the full study for all remaining authors’ financial disclosures.

Corneal collagen cross-linking improved maximum K value and corrected and uncorrected distance visual acuity in eyes with corneal ectasia at 1 year, according to a study in Ophthalmology.

A total of 179 patients with corneal ectasia after previous refractive surgery were included.

One group underwent standard corneal collagen cross-linking (CXL) (treatment group), and the control group received riboflavin alone without removal of the epithelium.

In the treatment group, the maximum K value decreased by 0.7 D from baseline to 1 year. It decreased by 2.0 D or more in 14 eyes and increased 2.0 D or more in three eyes.

Corrected distance visual acuity improved by an average of 5.0 logarithm of the minimum angle of resolution (LogMAR) letters, according to researchers.

A total of 23 eyes gained 10 or more LogMAR letters, and three eyes lost 10 or more.

The recent FDA approval of CXL for both the indications of progressive keratoconus and ectasia after refractive surgery represents a major advance in clinical care,” the researchers wrote. – by Abigail Sutton

Disclosure : Hersh is a medical monitor and consultant for Avedro. Please see the full study for all remaining authors’ financial disclosures.